eShowcase: PharmaReady V3.0
Document management suite gets training records tool with eCTD capabilities slated for V4.0
Document management suite gets training records tool with eCTD capabilities slated for V4.0
TAKE Solutions, Inc. (Princeton, NJ) stepped up the power of its PharmaReady document management suite by adding a training records management system in the software's version 3.0 release. The management software, which utilizes Microsoft Windows technology, is fully FDA 21 CFR Part 11, cGMP, and HIPAA compliant. It is designed specifically for SOPs, work instructions, training records, submission documents, and all other documents within FDA-regulated business areas.
Features present in the latest release include Active Directory authentication, email reminders, expanded reader assignment features, and advanced PDF publishing capabilities.
TAKE Solutions also announced launch plans for Version 4.0 to include fully structured product labeling and eCTD modules. Then, clinical documents stored in DMS today will automatically migrate into the eCTD module for compilation, publishing, and regulatory submission.
TAKE Solutions, Inc., (888) 993-1541, www.PharmaReady.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
